Novel Drug for Menopause Symptoms Passes Phase 3 Test

The novel NK3 receptor-inhibitor fezolinetant controlled vasomotor symptoms of menopause over 52 weeks in the phase 3 SKYLIGHT 2 trial.
Medscape Medical News

source https://www.medscape.com/viewarticle/975711?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?